Table 2. Relapse-free survivals and overall survivals in subgroup analysis according to clinicopathological factors.

Characteristics	Relapse-free survivals (95% CI)				Overall survivals (95% CI)
	Low immune score PT	High immune score PT	P value		Low immune score PT	High immune score PT	P value
Synchronous metastases
Present	26.90 (14.16–39.64)	19.13 (10.58–27.69)	0.551		43.10 (32.08–54.12)	64.37 (30.75–97.98)	0.576
Absent	30.57 (9.63–51.51)	8.67 (7.16–10.17)	0.769		38.30 (36.18–40.42)	35.37 (18.48–52.26)	0.491
Preoperative chemotherapy
Yes	12.43 (0.88–23.99)	19.07 (4.59–33.54)	0.847		28.67 (25.34–32.00)	64.37 (not reached)	0.354
No	30.50 (21.10–39.90)	19.23 (5.51–32.95)	0.862		47.20 (24.82–69.58)	65.40 (9.43–121.37)	0.642
Primary tumor location
Right-sided	37.5 (22.40–52.60)	19.07 (8.75–29.39)	0.360		47.20 (13.92–80.48)	Not reached	0.971
Left-sided	21.03 (5.42–36.65)	19.23 (6.40–32.07)	0.926		37.57 (29.55–45.59)	64.37 (16.41–112.32)	0.450
Resection status
Synchronous	36.87 (21.52–52.21)	19.23 (12.86–25.61)	0.594		47.20 (Not reached)	65.4 (not reached)	0.712
Heterochronous	12.43 (2.05–22.86)	13.13 (0.00–26.84)	0.811		36.13 (27.21–45.05)	64.37(not reached)	0.487
Chemotherapy before synchronous resection
Yes	37.50 (not reached)	19.13 (1.40–36.87)	0.970		23.83 (2.47–45.20)	Not reached	0.588
No	36.87 (not reached)	21.23 (not reached)	0.700		Not reached	Not reached	0.837
Chemotherapy before hepatectomy in heterochronous resection
Yes	8.67 (6.83–10.51)	9.37 (4.14–14.60)	0.851		30.50 (23.78–37.22)	Not reached	0.360
No	30.57 (10.82–50.31)	Not reached	0.580		38.30 (19.49–57.11)	64.37 (not reached)	0.850

CI, confidence interval; PT, primary tumor.